touchCARDIO touchCARDIO
Heart Failure
Read Time: 2 mins

36/Optimising pacemaker therapy using multi-point pacing (the OPT-MPP Study)

Copy Link
Published Online: Oct 9th 2012 European Journal of Arrhythmia & Electrophysiology. 2022;8(Suppl. 1):abstr36
Authors: JE Lowry – University of Leeds, Leeds; S Straw – University of Leeds, Leeds; CA Cole – University of Leeds, Leeds; MF Paton – University of Leeds, Leeds; MT Kearney – University of Leeds, Leeds; KK Witte – University of Leeds, Leeds; J Gierula (Presenting Author) – University of Leeds, Leeds
Quick Links:
Article
Article Information
Article:

Background: Heart failure with reduced ejection fraction (HFrEF) is characterised by an attenuation of the positive relationship between heart rate and left ventricular (LV) contractility, known as the force-frequency relationship (FFR). Optimal therapy for around 1/3 of people with HFrEF includes a resynchronisation (CRT) cardiac implantable electronic device (CIED). We have previously demonstrated that programming the CIED to maintain the heart rate within a range for optimal cardiac contractility is associated with improved exercise capacity. Multi-point pacing (MPP) has been proposed as a method of improving CRT. Whilst MPP allows the opportunity to pace the heart over a wider area, there is no consistent improvement in terms of cardiac structure and function.

Purpose: To explore the effect of MPP on the FFR, exercise capacity and cardiac function.

Methods: A double-blind, randomised, crossover study explored the acute effects of MPP on the FFR, left ventricular function and acute exercise capacity. In random order, participants underwent an FFR assessment, and a treadmill walk test, once with MPP activated and once with standard CRT settings. The CIED was programmed back to the pre-test standard CRT settings after each treadmill test.

Results: A total of 23 people were recruited. We found no differences between phases in resting LV ejection fraction. There was an acute improvement in peak cardiac contractility of borderline statistical significance (2.37 ± 1.3 vs 2.12 ± 1.08; p=0.05), and a reduction in LV end systolic volume index ((65.9 ± 30.1 mL vs 72.7 ± 34.5 mL), mean difference between the groups of 11.5 mL (95% CI 1.8–11.8; p=0.01)) and LV end diastolic volume index (95.3 ± 38.1 mL vs 102 ± 40.8 mL; mean difference between the groups 6.7 mL [95% CL 0.26–13.1; p=0.04]). These acute improvements in cardiac function and volume did not lead to an improvement in treadmill walk time in the entire cohort.

Conclusion: MPP acutely improves peak cardiac contractility and induces reverse remodelling. However, this did not lead to an improvement in treadmill walk time. 

Further Resources

Share this Article
Related Content In Heart Failure
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72